Last reviewed · How we verify
NCT05097898: CHF-COV-P
Chronic Heart Failure With Preserved Ejection Fraction - COngestion eValuation
NA trial testing Clinical examination centered on congestion in Chronic Heart Failure in 200 participants. Currently enrolling.
10 December 2028
Quick facts
| Lead sponsor | Central Hospital, Nancy, France |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 200 |
| Start date | 10 August 2022 |
| Primary completion | 10 December 2028 |
| Estimated completion | 10 June 2029 |
| Sites | 1 location across France |
Drugs / interventions tested
- Clinical examination centered on congestion
- Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography
- Blood and urine sample retrieved for biological assessment and biobanking
- Telephone follow-up
- Kansas City Cardiomyopathy Questionnaire (KCCQ)
Conditions studied
- Chronic Heart Failure — all drugs for Chronic Heart Failure →
- Preserved Ejection Fraction — all drugs for Preserved Ejection Fraction →
Sponsor
Central Hospital, Nancy, France
Who can join
18 and older, any sex, with Chronic Heart Failure or Preserved Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation. The main objective of the CHF-COV Preserved study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF with preserved left ventricular ejection fraction that are associated with the risk of all-cause death, hospitalization for acute HF or IV diuretics injection in a day hospital.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05097898
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Clinical examination centered on congestion
Trials testing the same drug.
- NCT05089162 — CHF-COV Reduced (Chronic Heart Failure With Reduced Ejection Fraction - COngestion eValuation) · NA · recruiting
- NCT05089149 — Chronic Heart Failure - COngestion eValuation · NA · recruiting
- NCT04343430 — Acute Heart Failure With Preserved Ejection Fraction - COngestion Discharge Evaluation · NA · recruiting
- NCT04343443 — Acute Heart Failure With Reduced Ejection Fraction - COngestion Discharge Evaluation · NA · recruiting
- NCT04332692 — Acute Heart Failure - COngestion Discharge Evaluation · NA · recruiting
Other recruiting trials for Chronic Heart Failure
Currently open trials in the same condition.
- NCT07265349 — A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure · Phase 1, PHASE2 · recruiting
- NCT07379840 — A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South K · recruiting
- NCT07325942 — Effectiveness of Low -Versus High -Volume High -Intensity Interval Training in Patients With Chronic Heart Failure · NA · recruiting
- NCT07434193 — Biventricular or Left Bundle Branch Pacing to Assess the Effect of Cardiac Resynchronization Therapy in Patients Undergo · NA · recruiting
- NCT07405944 — Vericiguat and Reverse Remodeling Indices in Heart Failure · Phase 4 · recruiting
Other Central Hospital, Nancy, France trials
Trials by the same sponsor.
- NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
- NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
- NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
- NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
- NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05097898 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
- Last refreshed: 5 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05097898.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing